LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Akciju saraksts・Coherus Oncology Inc

Coherus Oncology Inc

Slēgts

SektorsVeselības aprūpe

1.44 -8.86

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.44

Max

1.46

Galvenie mērījumi
By Trading Economics
Ienākumi	-278M -37M
Pārdošana	-438K 12M
P/E Sektora vidējais	3.509 49.888
EPS	-0.25
Peļņas marža	-300.041
Darbinieki	145
EBITDA	7.9M -35M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+468.97% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 6. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-17M 242M
Iepriekšējā atvēršanas cena	10.3
Iepriekšējā slēgšanas cena	1.44

Ziņu noskaņojums

By Acuity

100%

318 / 344 Rangs Healthcare

Coherus Oncology Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. jūn. 19:20 UTC

Galvenie tirgus virzītāji

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026. g. 6. jūn. 08:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 6. jūn. 08:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 6. jūn. 04:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. jūn. 00:14 UTC

Iegādes, apvienošanās, pārņemšana

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

2026. g. 5. jūn. 21:27 UTC

Peļņas

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 20:20 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026. g. 5. jūn. 20:19 UTC

Iegādes, apvienošanās, pārņemšana

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026. g. 5. jūn. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 5. jūn. 19:26 UTC

Tirgus saruna

Hog Futures Tumble to Close Week -- Market Talk

2026. g. 5. jūn. 19:10 UTC

Tirgus saruna

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026. g. 5. jūn. 19:03 UTC

Tirgus saruna

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026. g. 5. jūn. 18:59 UTC

Tirgus saruna

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026. g. 5. jūn. 18:47 UTC

Tirgus saruna

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026. g. 5. jūn. 18:34 UTC

Tirgus saruna

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026. g. 5. jūn. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026. g. 5. jūn. 17:50 UTC

Peļņas

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026. g. 5. jūn. 17:27 UTC

Tirgus saruna

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026. g. 5. jūn. 16:48 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 5. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 5. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 5. jūn. 15:44 UTC

Iegādes, apvienošanās, pārņemšana

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026. g. 5. jūn. 15:26 UTC

Tirgus saruna

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

2026. g. 5. jūn. 15:25 UTC

Peļņas

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

2026. g. 5. jūn. 15:16 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Coherus Oncology Inc Prognoze

Cenas mērķis

By TipRanks

468.97% augšup

Prognoze 12 mēnešiem

Vidējais 8.25 USD 468.97%

Augstākais 12 USD

Zemākais 4 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Coherus Oncology Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Coherus Oncology Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

318 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.